专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3169814A1 METHODS FOR EVALUATING LUNG CANCER STATUS 有权转让
标题翻译：评估肺癌状况的方法
公开(公告)号：EP3169814A1
公开(公告)日：2017-05-24
申请号：EP15822338.8
申请日：2015-07-14
申请人： Allegro Diagnostics Corp.
发明人： WHITNEY, Duncan H. , ELASHOFF, Michael
IPC分类号： C12Q1/68 , G01N33/574 , C40B40/08
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , G01N2033/57453 , G06F19/20 , G06F19/24
摘要： The disclosure in some aspects provides methods of determining the likelihood that a subject has lung cancer based on the expression of informative-genes. In other aspects, the disclosure provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the disclosure.
摘要翻译：本公开内容在一些方面提供了基于信息基因的表达确定受试者患有肺癌的可能性的方法。在其它方面，本公开提供了用于基于信息基因的表达来确定对象的适当诊断干预计划的方法。本公开的其他方面提供了相关的组合物和试剂盒。

2. 发明公开

EP2850229A1 SRM/MRM ASSAY FOR SUBTYPING LUNG HISTOLOGY 审中-公开
标题翻译： SRM / MRM测定法下的键入肺组织
公开(公告)号：EP2850229A1
公开(公告)日：2015-03-25
申请号：EP13790060.1
申请日：2013-05-16
申请人： Expression Pathology, Inc.
发明人： KRIZMAN, David B. , LIAO, Wei-Li , THYPARAMBIL, Sheeno , HEMBROUGH, Todd
IPC分类号： C40B30/10
CPC分类号： G01N33/57492 , G01N33/57423 , G01N33/57484 , G01N33/6848 , G01N2033/57453 , G01N2333/47 , G01N2333/4704 , G01N2333/4742 , G01N2333/70596 , G01N2333/96472 , G01N2458/15 , G01N2560/00
摘要： The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue™ reagents and protocol and the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a KRT5, KRT7, NapsinA, TTF1, TP63, and MUC1 fragment peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.

3. 发明公开

EP2850229A4 SRM/MRM ASSAY FOR SUBTYPING LUNG HISTOLOGY 审中-公开
标题翻译： SRM / MRM-ASSAY ZUR UNTERTYPISIERUNG EINER LUNGENHISTOLOGIE
公开(公告)号：EP2850229A4
公开(公告)日：2016-02-17
申请号：EP13790060
申请日：2013-05-16
申请人： EXPRESSION PATHOLOGY INC
发明人： KRIZMAN DAVID B , LIAO WEI-LI , THYPARAMBIL SHEENO , HEMBROUGH TODD
IPC分类号： C40B30/10 , G01N33/574 , G01N33/68
CPC分类号： G01N33/57492 , G01N33/57423 , G01N33/57484 , G01N33/6848 , G01N2033/57453 , G01N2333/47 , G01N2333/4704 , G01N2333/4742 , G01N2333/70596 , G01N2333/96472 , G01N2458/15 , G01N2560/00
摘要： The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from said biological sample using the Liquid Tissue™ reagents and protocol and the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a KRT5, KRT7, NapsinA, TTF1, TP63, and MUC1 fragment peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
摘要翻译：目前的公开内容提供了来自KRT5，KRT7，NapsinA，TTF1，TP63和/或MUC1蛋白的特定肽和衍生的电离特征，其特别有利于定量KRT5，KRT7，NapsinA，TTF1，TP63，和/或MUC1蛋白直接在已经通过选择反应监测（SRM）质谱法的方法固定在福尔马林中的生物样品中，或者也可以称为多反应监测（MRM）质谱法。这些生物样品被化学保存和固定，其中所述生物样品选自用含甲醛的试剂/固定剂（包括福尔马林固定的组织/细胞，福尔马林固定/石蜡包埋的（FFPE）组织/细胞，FFPE组织块）和来自这些区块的细胞和已被福尔马林固定和石蜡包埋的组织培养细胞。使用Liquid Tissue TM试剂和方案从所述生物样品制备蛋白质样品，并且通过SRM / MRM质量的方法在Liquid Tissue TM样品中定量KRT5，KRT7，NapsinA，TTF1，TP63和/或MUC1蛋白质通过在蛋白质样品中定量至少一种或多种所述的肽来进行光谱测定。如果它们以修饰或未修饰的形式存在，则可定量这些肽。 KRT5，KRT7，NapsinA，TTF1，TP63和MUC1片段肽的修饰形式的实例是肽序列内的酪氨酸，苏氨酸，丝氨酸和/或其他氨基酸残基的磷酸化。

4. 发明公开

EP3176183A1 COMPOSITIONS AND METHODS FOR TREATING CANCER NOT RESISTANT TO A TYROSINE KINASE INHIBITOR (TKI) 审中-公开
标题翻译：组合物和用于治疗癌症无阻力针对酪氨酸激酶抑制剂的方法（TKI）
公开(公告)号：EP3176183A1
公开(公告)日：2017-06-07
申请号：EP16201602.6
申请日：2016-12-01
申请人： Yeda Research and Development Co. Ltd
发明人： YARDEN, Yosef , MANCINI, Maicol , GABORIT, Nadège
IPC分类号： C07K16/28 , C07K16/32 , A61P35/00 , A61K39/395 , C07K16/30 , A61K33/24 , A61K39/00 , G01N33/574
CPC分类号： C07K16/2863 , A61K31/506 , A61K39/39558 , A61K2039/507 , C07K16/32 , C07K2317/24 , G01N2033/57453 , A61K2300/00
摘要： Compositions for use in the treatment of cancer are provided. Accordingly, there is provided tyrosine kinase inhibitor (TKI) and antibodies comprising an anti-EGFR anti body, an anti-H E R2 anti body and an anti-H E R3 anti body, for use in the treatment of cancer not resistant to a TKI.
摘要翻译：提供用于治疗癌症的组合物。因此，提供了一种酪氨酸激酶抑制剂（TKI）和抗体，其包含抗EGFR抗体抗HËR2抗体和抗HËR3抗体的，其用于治疗癌症的抗不 TKI。

5. 发明公开

EP3039428A1 NONINVASIVE DETECTION OF LUNG CANCER USING EXHALED BREATH 审中-实审
标题翻译： NICHTINVASIVER NACHWEIS VON LUNGENKREBS MITTELS AUSATEMLUFT
公开(公告)号：EP3039428A1
公开(公告)日：2016-07-06
申请号：EP14762190.8
申请日：2014-08-28
申请人： University Of Louisville Research Foundation, Inc.
发明人： FU, Xiaoan , NANTZ, Michael , BOUSAMRA, Michael
IPC分类号： G01N33/543 , G01N30/08 , G01N33/497 , G01N33/574 , G01N33/64
CPC分类号： G01N33/57423 , G01N1/405 , G01N33/543 , G01N33/57484 , G01N33/64 , G01N2033/4975 , G01N2033/57453
摘要： A non-invasive method of detecting or screening for lung cancer in a subject specimen is provided. The method includes detecting elevated levels of one or more carbonyl-containing volatile organic compounds (VOCs) that are biomarkers for lung cancer in exhaled breath from the subject specimen. The method may further include obtaining exhaled breath from the subject specimen; forming adducts of the carbonyl-containing VOCs with a reactive chemical compound; quantifying the adducts of the carbonyl-containing VOCs to establish a subject value for each of the adducts; and comparing each subject value to a threshold healthy specimen value for each of the adducts of the carbonyl-containing VOCs. One or more subject values at quantities greater than threshold healthy specimen values are also useful for screening for lung cancer in the subject specimen.
摘要翻译：提供了一种在受试者标本中检测或筛选肺癌的非侵入性方法。该方法包括检测作为来自受检标本的呼出气中肺癌生物标志物的一种或多种含羰基挥发性有机化合物（VOC）的升高水平。所述方法还可以包括从所述受检标本获得呼出的呼吸; 形成含羰基VOC的加成物与活性化合物; 量化含羰基VOC的加合物以建立每种加合物的对象值; 并将每个受试者值与含羰基VOC的加合物的阈值健康标本值进行比较。一个或多个数量大于阈值健康标本值的受试者值也可用于筛选受检标本中的肺癌。

6. 发明公开

EP1806581A1 DISEASE DIAGNOSING SYSTEM 审中-公开
标题翻译： KRANKHEITSDIAGNOSESYSTEM
公开(公告)号：EP1806581A1
公开(公告)日：2007-07-11
申请号：EP05799295.0
申请日：2005-10-26
申请人： Seems Inc.
发明人： URUSHIHATA, Naoki, c/o SEEMS Inc , TANEMURA, Hideki, c/o SEEMS Inc , TAJIMA, Yukinobu, c/oSEEMS Inc , HIROHAMA, Syuji, c/o SEEMS Inc
IPC分类号： G01N33/497 , G01N33/50
CPC分类号： G01N33/497 , A61B5/00 , A61B5/082 , A61B10/0038 , A61B10/0045 , A61B10/0064 , A61B10/007 , A61B2010/0087 , G01N2033/57453
摘要： [Problem]
To provide a disease diagnostic system capable of diagnosing with high accuracy whether a subject is afflicted with a disease, without inflicting pain on the subject.
[Means for Resolution]
The disease diagnostic system includes collecting means (5) for collecting a substance (e.g., aspiration, sweat, human waste or urine) emitting an odor (e.g., mouth odor, body odor or underarm odor) and storing the same therein, measuring means (10) for measuring whether an indicated substance indicative of the existence of a disease is contained in the odor-emitting substance stored in the collecting means (5), and control means (20) for processing a signal indicative of a result of measurement by the measuring means (10) to determine whether the subject (2) is being afflicted with a disease.
摘要翻译： [问题]提供能够高精度地诊断受试者是否患有疾病的疾病诊断系统，而不会对受试者造成疼痛。 [解决手段]疾病诊断系统包括收集装置（5），用于收集发出异味（例如口腔气味，体臭或腋臭）的物质（例如吸入，汗液，人体废物或尿液）并将其储存其中，用于测量存储在收集装置（5）中的气味发射物质中是否包含指示疾病存在的指示物质的测量装置（10），以及用于处理指示由测量装置（10）测量的结果以确定受试者（2）是否患有疾病。

7. 发明公开

EP3313861A1 NOVEL KININ-BASED THERANOSTIC PROBES FOR SOLID CANCERS AND USES THEREOF 审中-公开
标题翻译：新的基于Kinin的固体癌症治疗探针及其应用
公开(公告)号：EP3313861A1
公开(公告)日：2018-05-02
申请号：EP16813436.9
申请日：2016-06-23
申请人： Société de commercialisation des produits de la recherche appliquée SOCPRA Sciences Santé et Humaines s.e.c.
发明人： GOBEIL, Fernand , GUERIN, Brigitte , LEPAGE, Martin , SABBAGH, Robert , FORTIN, David
IPC分类号： C07K7/06 , A61K51/04 , A61K51/08 , C07K7/18 , C07K14/705
CPC分类号： A61K51/088 , A61K38/043 , A61K2123/00 , C07K1/13 , C07K7/06 , C07K7/18 , C07K14/723 , G01N33/57434 , G01N2033/57403 , G01N2033/57453
摘要： It is provided new chemical entities allowing simultaneous diagnosis and treatment of cancers. More specifically, it is provided a theranostic compound consisting of a stabilized peptide ligand (agonists and antagonists) for the kinin B1 receptors (B1R) conjugated to specific radionuclides (e.g. 64Cu) suitable for dual imaging/radiotherapy applications.

8. 发明公开

EP3169814A4 METHODS FOR EVALUATING LUNG CANCER STATUS 有权转让
公开(公告)号：EP3169814A4
公开(公告)日：2018-03-07
申请号：EP15822338
申请日：2015-07-14
申请人： VERACYTE INC
发明人： WHITNEY DUNCAN H , ELASHOFF MICHAEL
IPC分类号： C12Q1/6886 , C40B40/08 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , G01N2033/57453 , G06F19/20 , G06F19/24
摘要： The disclosure in some aspects provides methods of determining the likelihood that a subject has lung cancer based on the expression of informative-genes. In other aspects, the disclosure provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the disclosure.

9. 发明公开

EP1806581A4 DISEASE DIAGNOSING SYSTEM 审中-公开
标题翻译：疾病诊断系统
公开(公告)号：EP1806581A4
公开(公告)日：2011-08-17
申请号：EP05799295
申请日：2005-10-26
申请人： SEEMS INC
发明人： URUSHIHATA NAOKI , TANEMURA HIDEKI , TAJIMA YUKINOBU , HIROHAMA SYUJI
IPC分类号： G01N33/497 , G01N33/50
CPC分类号： G01N33/497 , A61B5/00 , A61B5/082 , A61B10/0038 , A61B10/0045 , A61B10/0064 , A61B10/007 , A61B2010/0087 , G01N2033/57453

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式